Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
19.50
-1.58 (-7.50%)
At close: Mar 18, 2026, 4:00 PM EDT
19.31
-0.19 (-0.97%)
Pre-market: Mar 19, 2026, 4:02 AM EDT
Neurogene Employees
Neurogene had 107 employees as of December 31, 2024. The number of employees increased by 16 or 17.58% compared to the previous year.
Employees
107
Change (1Y)
16
Growth (1Y)
17.58%
Revenue / Employee
n/a
Profits / Employee
-$795,607
Market Cap
302.05M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 107 | 16 | 17.58% |
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Jun 30, 2023 | 82 | - | - |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| AC Immune | 172 |
| Nautilus Biotechnology | 130 |
| Silence Therapeutics | 88 |
| Immuneering | 53 |
| NovaBridge Biosciences | 32 |
| Climb Bio | 29 |
| Opus Genetics | 18 |
NGNE News
- 7 days ago - Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Business Wire
- 15 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 5 weeks ago - Neurogene to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - Business Wire
- 2 months ago - Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - Neurogene: From Speculation To Execution With NGN-401 - Seeking Alpha